Kura Oncology announced on April 17, 2026, that its drug darlifarnib, in combination with cabozantinib, showed significant activity in a subset of clear cell renal cell carcinoma patients who had previously been treated with cabozantinib, potentially offering a new option for a treatment-resistant population.
"These data support the potential of darlifarnib to overcome resistance and resensitize tumors to VEGF TKI therapy," a Kura Oncology representative said in a statement.
The data comes from a subset analysis of an ongoing clinical trial investigating the combination therapy. While Kura Oncology described the clinical activity as "robust," specific metrics on overall response rate, duration of response, and progression-free survival were not disclosed in the initial announcement. The trial focuses on patients with clear cell renal cell carcinoma, which accounts for approximately 75% of all kidney cancer cases.
This development is significant for Kura Oncology as it addresses a key challenge in cancer therapy: acquired resistance to treatment. Many patients with renal cell carcinoma are treated with tyrosine kinase inhibitors (TKIs) like cabozantinib, but their tumors often develop resistance over time, limiting long-term efficacy. A combination therapy that can re-sensitize tumors to treatment could represent a major clinical advance and a substantial commercial opportunity.
Cabozantinib, marketed by Exelixis as Cabometyx, is a standard of care in renal cell carcinoma. However, the eventual development of resistance is a primary driver of treatment failure. Darlifarnib is an investigational, oral, small molecule inhibitor of the fibroblast growth factor receptor (FGFR). The scientific rationale for the combination is that blocking both the VEGF receptor (targeted by cabozantinib) and the FGFR pathway could create a more durable anti-tumor response and prevent or overcome resistance.
The positive subset analysis provides the first clinical evidence supporting this hypothesis in patients who have already progressed on cabozantinib. This suggests a potential new treatment sequence for patients who have exhausted current options, a population with high unmet medical need.
For Kura Oncology, these results could significantly de-risk the darlifarnib program and attract investor and partner interest. The company's stock will likely see a significant positive reaction to the news. The potential to expand the addressable market for darlifarnib into the treatment-resistant setting is a major value driver.
The renal cell carcinoma market is competitive, with major players including Pfizer, Merck, and Bristol-Myers Squibb. However, a therapy that specifically addresses cabozantinib resistance would have a well-defined and valuable niche. Investors will be closely watching for the full data set from the clinical trial, which the company is expected to present at an upcoming medical conference. The success of this combination could position Kura as a key player in the next generation of kidney cancer therapies. Kura Oncology has indicated it has a cash runway sufficient to fund operations through the next phase of darlifarnib's development.
This article is for informational purposes only and does not constitute investment advice.
